Every company starts somewhere. Adderall is Elite’s beginning (after many years with poor decisions) to keep the operating cash flow driving R&D. They are on track to outperform history in top line and profitability. Pissed investors are growing wary of the slower than hare progress, but progress is being made nonetheless. CEO has fuzzy history on the ability to execute. I think he has the partners in place to successfully transition away from Lannett. We’ll see whether a CFO can put up with things long enough to stick around for their annual review.
News 
Market Data 
Discover 
